title: Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
abstract: In the last 20 years, the survival and quality of life outcomes for patients with metastatic melanoma have been poor, with unsatisfactory results of chemotherapy and immunotherapy-based regimens. No drug or combination of drugs had any impact on survival until 2011, when ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4), was approved for clinical use. Phase III trials have shown, for the first time ever, an overall survival benefit of ipilimumab compared with standard treatment, with a manageable toxicity profile. This review will discuss the mechanism of action of ipilimumab and the clinical trials that led to its approval.
authors: Paolo A
authors: PA
authors: Ascierto
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D002352:Carrier Proteins / Q000276:immunology / Q000378:metabolism; D002986:Clinical Trials as Topic; D017277:Drug Approval; D019317:Evidence-Based Medicine; D006801:Humans; D000074324:Ipilimumab; D007558:Italy; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D011994:Recombinant Proteins / Q000276:immunology / Q000378:metabolism; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D015996:Survival Rate; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C468140:CD28-binding protein, human; D060908:CTLA-4 Antigen; D002352:Carrier Proteins; D000074324:Ipilimumab; D011994:Recombinant Proteins; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf